Generated by All in One SEO v4.9.7.2, this is an llms.txt file, used by LLMs to index the site.

# Opticyte

The World’s Only Cell O₂ Monitor

## Sitemaps

- [XML Sitemap](https://www.opticyte.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://www.opticyte.com/news/)
- [Opticyte Selected for MedTech Accelerator 2023 Cohort](https://www.opticyte.com/2023/06/12/opticyte-selected-for-medtech-accelerator-2023-cohort/) - Opticyte, Inc. was recently announced as one of 61 medical technology start-ups to be selected for the MedTech Innovator 2023 Cohort. This year’s cohort was highly competitive, with only 5% of applicants accepted into the accelerator. Opticyte joins top medical device, digital health, and diagnostic companies from around the world in the four-month program. MedTech
- [Opticyte a Sponsor of Unite for Sepsis Symposium](https://www.opticyte.com/2026/06/09/opticyte-a-sponsor-of-unite-for-sepsis-symposium/) - Opticyte is a sponsor of the second annual Unite for Sepsis Symposium in Washington DC this week, where CEO Lori Arakaki is a featured speaker. This event brings together clinicians, researchers, technologists, policymakers, and advocates dedicated to advancing innovation in sepsis prevention, diagnosis, treatment, and recovery. We're grateful to the Sepsis Alliance for hosting this
- [Featured Speaker at Unite for Sepsis Symposium](https://www.opticyte.com/2026/06/03/featured-speaker-at-unite-for-sepsis-symposium/) - From CEO Lori Arakaki: "Sepsis takes a life every two seconds. That statistic never stops being staggering, and it's exactly why I'm honored to speak at the Unite for Sepsis Symposium next week. Hosted by Sepsis Alliance (June 11–12, 2026), this symposium brings together the people working hardest to change those numbers. I'm proud to
- [CEO Lori Arakaki at SCCM's Critical Care Congress](https://www.opticyte.com/2026/04/02/ceo-lori-arakaki-at-sccms-critical-care-congress/) - Opticyte CEO Lori Arakaki presented at an event sponsored by MTEC | Medical Technology Enterprise Consortium. The event was on innovations that could serve the military, and her presentation focused on how Opticyte's novel cellular oxygenation monitoring could improve survival from battlefield trauma. The event was part of The Society of Critical Care Medicine's (SCCM) annual Critical
- [FDA Grants 2nd Breakthrough Device Designation](https://www.opticyte.com/2025/04/04/fda-grants-2nd-breakthrough-device-designation/) - We are thrilled to announce that Opticyte has been awarded a second FDA Breakthrough Device Designation for our pulse oximetry technology. This recognition comes on the heels of our first BDD for our Cell O2 technology in 2022, marking an achievement of receiving two Breakthrough Designations for a single device. ▶️ Why This Matters:The FDA’s
- [Opticyte Named a Top 10 Medical Device Innovator](https://www.opticyte.com/2025/06/19/opticyte-featured-in-inc-media-magazine/) - Opticyte is pioneering medical innovation with VitalO2, a ground-breaking noninvasive device that delivers two critical measurements: cellular oxygenation (Cell O2) and accurate pulse oximetry for all skin tones. By harnessing the power of optical spectroscopy and machine learning, VitalO2 will enable clinicians to deliver personalized and optimized care to critically ill patients. Under the visionary
- [What We Learned from World Sepsis Congress](https://www.opticyte.com/2025/04/28/what-we-learned-from-world-sepsis-congress/) - Earlier this month, our CEO Lori Arakaki had the opportunity to attend part of the World Sepsis Congress, a global gathering of experts, clinicians, and advocates focused on one of healthcare’s most devastating and costly conditions. The sessions focused mainly on the long-term consequences of surviving sepsis - an area that’s often underreported, yet deeply
- [What Doctors Are Saying About VitalO2](https://www.opticyte.com/2025/05/14/what-doctors-are-saying-about-vitalo2/) - Doctors on the frontlines of critical care know the painful truth: Today’s tools often detect sepsis, trauma, and respiratory failure too late to prevent serious complications. We believe that is why clinicians are excited about Opticyte's VitalO₂ Monitor. "In critically ill patients, we currently rely on indirect measures to evaluate tissue perfusion. VitalO₂'s direct measurement
- [Become an Investor: StartEngine Campaign Closing Soon](https://www.opticyte.com/2025/06/09/become-an-investor-startengine-campaign-closing-soon/) - We’re excited to share that Opticyte is entering the final month of our StartEngine campaign. With over $235,000 raised on StartEngine, plus additional outside investment through a convertible note, our community continues to grow. We’re incredibly proud of the support we’ve received from investors who share our vision to potentially transform patient monitoring and health
- [Don't Miss Doug Baldwin Jr. & CEO Lori Arakaki June 11](https://www.opticyte.com/2025/06/11/dont-miss-doug-baldwin-jr-ceo-lori-arakaki-june-11/) - Don’t Miss Doug Baldwin Jr & Lori Arakaki on June 11 You’re invited to a powerful conversation on the future of healthcare access, equity, and innovation. 🎙 Live Webinar with:🗣 Lori Arakaki, CEO of Opticyte🗣 Doug Baldwin, Founder of Vault89, Opticyte investor, and Super Bowl Champion🗣 Angela Poe Russell, TV Journalist, Gracie & Emmy Award Winner, will moderate📅 Date:
- [Real Breakthroughs Don't Happen Overnight](https://www.opticyte.com/2025/05/28/real-breakthroughs-dont-happen-overnight/) - Real breakthroughs don’t happen overnight. They take years of persistence, discovery, and vision. Opticyte’s VitalO₂ Monitor traces its roots back more than 30 years, to PhD research on cellular oxygenation by our CEO and Co-Founder, Lori Arakaki, PhD. Since then, Lori and our team have spent decades advancing the science of optical spectroscopy, building from
- [Looking Ahead to 2025](https://www.opticyte.com/2025/01/09/looking-ahead-to-2025/) - As the new year dawns, we want to take a moment to thank each of you for being part of our journey. Whether you’ve followed us, supported our work, or shared our mission with others, your encouragement means the world to us. At Opticyte, we believe that innovation can save lives—and that belief is stronger
- [CEO Lori Arakaki On Racial Bias in Pulse Oximetry](https://www.opticyte.com/2024/07/24/ceo-lori-arakaki-on-racial-bias-in-pulse-oximetry/) - In a few short months, we’ll mark the 5 year anniversary of the start of COVID-19 pandemic. I remember it well, as Opticyte and our commitment to advance health equity was underway with our work to develop cellular oximetry technology to work effectively for all skin tones. At the start of the COVID-19 pandemic, I
- [New FDA Paper on Health Equity For Medical Devices](https://www.opticyte.com/2024/08/28/new-fda-paper-on-health-equity-for-medical-devices/) - Health equity champions, listen up and get ready to comment! The FDA's new discussion paper, "Health Equity For Medical Devices" is sparking conversations and helping build important momentum for change. We’re overdue to consider how we build clinical trial designs that prioritize diversity and inclusivity. Key points from the paper we’re reacting to: • How
- [September is Sepsis Awareness Month](https://www.opticyte.com/2024/09/03/september-is-sepsis-awareness-month/) - Join us during September as we focus on fighting the leading cause of death in US hospitals, during Sepsis Awareness Month. Together we can tackle this global threat. We’re sharing critical resources to help educate and advocate for change from the status quo from the Sepsis Alliance, the Global Sepsis Alliance and the Washington State
- [CEO Lori Arakaki at Optica MedTech Industry Summit](https://www.opticyte.com/2024/10/02/ceo-lori-arakaki-at-optica-medtech-industry-summit/) - Join me as I share insights from our studies at Opticyte with all those attending the upcoming Optica MedTech Industry Summit in Montreal! ?? I'll present our latest findings on how our VitalO₂ monitor technology is poised to help revolutionize care for sepsis, anemia, and vasoplegia. Our studies show promising results in detecting oxygen deficiency
- [Our Crowdfunding Campaign is Live!](https://www.opticyte.com/2024/10/31/our-crowdfunding-campaign-is-live/) - ? BIG NEWS ? Opticyte is now LIVE on StartEngine! With investment opportunities starting at $300 and bonuses at higher tiers of investing, you can now be part of our new crowdfunding campaign and support our mission to bring more effective, equitable healthcare to all. Your single investment helps address two critical and tragic crises facing healthcare today:
- [StartEngine Campaign Riding A Wave of Momentum](https://www.opticyte.com/2024/11/20/startengine-campaign-riding-a-wave-of-momentum/) - Exciting news! Thanks to investors like you, Opticyte is riding a wave of momentum after raising over $100,000 in just one week on StartEngine! ? Our mission: Ensuring accurate oxygen measurements across all skin tones and enabling early sepsis detection. ? Highlights:• $70,000+ raised in the first 24 hours• 50+ investors and growing We’re working
- [New Investment from FBomb Angels](https://www.opticyte.com/2024/12/05/new-investment-from-fbomb-angels/) - Thank you to the FBomb Angels for a meaningful investment that supports our mission to transform health equity and sepsis detection through our VitalO₂ monitor. We are the health equity change we want to see in the world. This new investment builds on the $2.5 million in venture capital and private investments already raised, alongside
- [Opticyte Featured in NIH Article](https://www.opticyte.com/2024/05/30/opticyte-featured-in-nih-article/) - Check out this article about our VitalO2 device from the NIH National Heart, Lung, and Blood Institute. Many thanks to NHLBI for SBIR support that has been absolutely essential in developing and demonstrating the clinical value of Cell O2 in sepsis and anemia. Thanks also to Stephanie M. Davis, Ph.D. of NHLBI for your ongoing support and
- [Opticyte: Why the Need is Now](https://www.opticyte.com/2020/12/11/opticyte-why-the-need-is-now/) - We’re solving a big problem in medicine at Opticyte and because of our work, I have no doubt lives will be saved. I’ve dedicated my career to researching, understanding, and building a new technology needed to reveal a critical, missing -- and life-saving -- insight for clinicians. Opticyte’s VitalO2 holds the promise of reducing organ failure
- [FDA Meeting on Pulse Oximeters](https://www.opticyte.com/2024/02/02/fda-meeting-on-pulse-oximeters/) - Attending today’s FDA public meeting on pulse oximeters has been inspiring. Here at Opticyte we are encouraged by the attention from clinicians, professional societies, regulators, industry stakeholders, and patient representatives on improving pulse oximetry performance for people of all skin tones. The problem with accuracy in individuals with darker skin tones is more and more
- [Creative Destruction Lab](https://www.opticyte.com/2024/05/08/creative-destruction-lab/) - Thanks to Creative Destruction Lab for including Opticyte as part of its recent CDL-Vancouver Alumni Showcase. It was a fantastic event where Lori Arakaki pitched our company and demoed the VitalO₂ technology, engaging in meaningful conversations with investors and other entrepreneurs. We're thankful to be part of a community of such ambitious, passionate innovators.
- [AdvaMed Medtech Conference](https://www.opticyte.com/2023/10/05/advamed-medtech-conference/) - Anyone going to AdvaMed The MedTech Conference in Anaheim, CA next week should check-out Lori Arakaki’s presentation as part of the Critical Care & Emergency Medicine session on Monday, October 9. It’s exciting to be showcasing the opportunity to save lives with our VitalO₂ device alongside so many luminaries and innovators in the MedTech ecosystem.
- [Women in MedTech](https://www.opticyte.com/2023/10/13/women-in-medtech/) - Was so wonderful for Lori Arakaki to connect with other MedTech Innovator women leaders this week at The MedTech Conference, learning from and being inspired by each other's successes. The conference was a busy, packed three days for Lori and Board Chair Robert Barry in Anaheim -- incredibly valuable from start to finish. The consistent
- [Device Talks Boston](https://www.opticyte.com/2024/04/29/device-talks-boston/) - This week Lori Arakaki will be headed to DeviceTalks Boston as part of the MedTech Innovator All-Stars Alumni Investor Forum. We're excited for her to get to connect with investors and other innovators in the MedTech space as she shares how our VitalO₂ device can transform identification and treatment of sepsis and organ failure. If
- [Opticyte Chosen As Finalist for MedTech Innovator Award](https://www.opticyte.com/2023/09/29/opticyte-chosen-as-finalist-for-medtech-innovator-award/) - We are thrilled to share that Opticyte is a finalist for the MedTech Innovator & AdvaMed Execution Award! This award recognizes strong leadership teams with next-generation innovations and the resources to successfully execute their goals of improving patient care. Opticyte was selected as one of the 5 finalists out of the 61 companies in the 2023 accelerator cohort. It
- [Opticyte Secures $4.6 Million in Funding to Develop First Cell O2 Monitor for Reducing Organ Failure](https://www.opticyte.com/2021/01/13/opticyte-secures-4-6-million-in-funding-to-develop-first-cell-o2-monitor-for-reducing-organ-failure/) - SEATTLE, Washington, January 12, 2020 – Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure, announced the recent culmination of private capital and grant funding. The $4.6MM in funding is enabling Opticyte to address sepsis–the primary
- [GeekWire: UW spinout Opticyte lands $4.6M to test device that quickly detects early signs of organ failure](https://www.opticyte.com/2021/01/13/geekwire-uw-spinout-opticyte-lands-4-6m-to-test-device-that-quickly-detects-early-signs-of-organ-failure/) - University of Washington biotech spinout Opticyte has landed $2.9 million in federal grants and $1.7 million in seed funding. The Seattle startup is developing a non-invasive technology that can detect oxygen levels in cells in real time. The Opticyte Cell O2 Monitor could help in the treatment of sepsis, which is an infection that runs amuck and can
- [CEO Lori Arakaki on Creating Successful Academic Spin-outs](https://www.opticyte.com/2021/02/17/ceo-lori-arakaki-on-creating-successful-academic-spin-outs/) - Join Opticyte Co-founder and CEO, Lori Arakaki, for a panel discussion, "Creating Successful Academic Spin-outs," hosted by StarFish Medical on Friday, February 26, 2021 at 10:00 AM Pacific Time. This live, 90-minute event will feature three distinguished academics/entrepreneurs discussing their Academic Spin-out successes, adventures and insights. The event is free, and more information and registration can be
- [Pacific Northwest Sepsis Conference](https://www.opticyte.com/2021/04/29/pacific-northwest-sepsis-conference/) - Opticyte and CEO Lori Arakaki will be participating as an exhibitor in the 9th annual Pacific Northwest Sepsis Conference next week, May 3-4. If you're attending, check out our virtual booth in the app and say hello!
- [CEO Lori Arakaki on Working with StarFish Medical](https://www.opticyte.com/2022/11/16/ceo-lori-arakaki-on-working-with-starfish-medical/) - StarFish Medical has been a top-notch partner for us. Check out our CEO Lori Arakaki talk about our Cell O₂ Patient Monitor technology and how StarFish's engineering and medical device design expertise has helped our product development.
- [<strong>Opticyte Earns FDA Breakthrough Device Designation for the First Cell O<sub>2</sub> Patient Monitor for Organ Failure</strong>](https://www.opticyte.com/2023/01/09/opticyte-earns-fda-breakthrough-device-designation-for-the-first-cell-o2-patient-monitor-for-organ-failure/) - SEATTLE, Washington, January 9, 2023– Opticyte, a medical device start-up, announced today that its Cell O2 Patient Monitor received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for real-time, continuous monitoring of patients at risk of organ failure. The Cell O2 Patient Monitor uses noninvasive optical spectroscopy technology to measure and detect

## Pages

- [Homepage](https://www.opticyte.com/) - The Opticyte Cell O₂ Monitor is the first device to measure oxygen levels inside cells in real-time.
- [Investors](https://www.opticyte.com/investors/)
- [About Us](https://www.opticyte.com/about-us/)
- [Technology](https://www.opticyte.com/technology/)
- [Contact Us](https://www.opticyte.com/contact-us/) - Please enable JavaScript in your browser to complete this form. Name * Company Email Address * Subject Message * Submit Opticyte, Inc. 4000 Mason Road, Suite 300Seattle, WA 98195
- [Financial Conflict of Interest Policy](https://www.opticyte.com/financial-conflicts-of-interest-policy/) - Policy Statement Opticyte is committed to protecting the integrity and objectivity of its research activities by ensuring that the design, conduct, and reporting of research will not be biased or appear to be biased by a personal financial conflict of interest. Opticyte has implemented this policy to identify, manage, reduce, or eliminate financial conflicts of
- [Attribution](https://www.opticyte.com/attribution/) - Coming soon.

## Research papers

- [Noninvasive Cellular Oxygenation Measurement During Graded Hypoxia Using Visible–Near-Infrared Spectroscopy](https://www.opticyte.com/_opticyte_paper/noninvasive-cellular-oxygenation-measurement-during-graded-hypoxia-using-visible-near-infrared-spectroscopy/) - Noninvasive Cellular Oxygenation Measurement During Graded Hypoxia Using Visible–Near-Infrared Spectroscopy
- [Assessment of Muscle Oxygenation in Children with Congenital Heart Disease](https://www.opticyte.com/_opticyte_paper/assessment-of-muscle-oxygenation-in-children-with-congenital-heart-disease/) - Assessment of Muscle Oxygenation in Children with Congenital Heart Disease
- [Optical spectroscopy to assess muscle oxygenation in infants undergoing extracorporeal life support](https://www.opticyte.com/_opticyte_paper/optical-spectroscopy-to-assess-muscle-oxygenation-in-infants-undergoing-extracorporeal-life-support/) - Optical spectroscopy to assess muscle oxygenation in infants undergoing extracorporeal life support
- [Non-invasive assessment of muscle oxygenation may aid in optimising transfusion threshold decisions in ambulatory paediatric patients](https://www.opticyte.com/_opticyte_paper/non-invasive-assessment-of-muscle-oxygenation-may-aid-in-optimising-transfusion-threshold-decisions-in-ambulatory-paediatric-patients/) - Non-invasive assessment of muscle oxygenation may aid in optimising transfusion threshold decisions in ambulatory paediatric patients
- [Muscle oxygenation as an early predictor of shock severity in trauma patients](https://www.opticyte.com/_opticyte_paper/muscle-oxygenation-as-an-early-predictor-of-shock-severity-in-trauma-patients/) - Muscle oxygenation as an early predictor of shock severity in trauma patients
- [Muscle oxygenation as an indicator of shock severity in patients with suspected severe sepsis or septic shock](https://www.opticyte.com/_opticyte_paper/muscle-oxygenation-as-an-indicator-of-shock-severity-in-patients-with-suspected-severe-sepsis-or-septic-shock/) - Muscle oxygenation as an indicator of shock severity in patients with suspected severe sepsis or septic shock

## Categories

- [News](https://www.opticyte.com/category/news/)